JP2020527547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527547A5 JP2020527547A5 JP2019572783A JP2019572783A JP2020527547A5 JP 2020527547 A5 JP2020527547 A5 JP 2020527547A5 JP 2019572783 A JP2019572783 A JP 2019572783A JP 2019572783 A JP2019572783 A JP 2019572783A JP 2020527547 A5 JP2020527547 A5 JP 2020527547A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- liver
- formula
- subject
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 210000004185 liver Anatomy 0.000 claims 10
- 239000003925 fat Substances 0.000 claims 9
- 208000010706 fatty liver disease Diseases 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 6
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 3
- 235000000346 sugar Nutrition 0.000 claims 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- HIWZHLUXGVVBPK-NZSKALFASA-N (3r)-butane-1,3-diol;(3r)-3-hydroxybutanoic acid Chemical compound C[C@@H](O)CCO.C[C@@H](O)CC(O)=O HIWZHLUXGVVBPK-NZSKALFASA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 claims 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 206010056474 Erythrosis Diseases 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000379 polymerizing effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023107837A JP7632979B2 (ja) | 2017-06-27 | 2023-06-30 | 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1710229.4A GB201710229D0 (en) | 2017-06-27 | 2017-06-27 | Compounds for new use |
| GB1710229.4 | 2017-06-27 | ||
| PCT/GB2018/051752 WO2019002828A1 (en) | 2017-06-27 | 2018-06-22 | 3-HYDROXYBUTYRATE COMPOUNDS FOR USE IN THE REDUCTION OF HEPATIC FAT |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023107837A Division JP7632979B2 (ja) | 2017-06-27 | 2023-06-30 | 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527547A JP2020527547A (ja) | 2020-09-10 |
| JP2020527547A5 true JP2020527547A5 (enExample) | 2021-07-29 |
| JP7374000B2 JP7374000B2 (ja) | 2023-11-06 |
Family
ID=59523693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572783A Active JP7374000B2 (ja) | 2017-06-27 | 2018-06-22 | 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物 |
| JP2023107837A Active JP7632979B2 (ja) | 2017-06-27 | 2023-06-30 | 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023107837A Active JP7632979B2 (ja) | 2017-06-27 | 2023-06-30 | 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12439944B2 (enExample) |
| EP (2) | EP3644982B1 (enExample) |
| JP (2) | JP7374000B2 (enExample) |
| KR (1) | KR102680437B1 (enExample) |
| CN (1) | CN110869012B (enExample) |
| AU (1) | AU2018293398B2 (enExample) |
| CA (1) | CA3066948A1 (enExample) |
| DK (1) | DK3644982T3 (enExample) |
| ES (1) | ES2945964T3 (enExample) |
| GB (2) | GB201710229D0 (enExample) |
| PL (1) | PL3644982T3 (enExample) |
| TW (1) | TWI811222B (enExample) |
| WO (1) | WO2019002828A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710229D0 (en) | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| GB201715654D0 (en) * | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| GB2577723A (en) | 2018-10-04 | 2020-04-08 | Tdeltas Ltd | Compounds for new use |
| JP7235873B2 (ja) * | 2019-01-17 | 2023-03-08 | アイオーアイ オレオ ゲーエムベーハー | ヒドロキシカルボン酸のグリセリドの製造方法 |
| CN109700021A (zh) * | 2019-03-04 | 2019-05-03 | 清华大学 | 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用 |
| CN110776425B (zh) * | 2019-10-23 | 2021-02-26 | 清华大学 | 一种(r)-3-羟基丁酸及其低聚物的制备方法 |
| JP7638693B2 (ja) * | 2020-12-15 | 2025-03-04 | 大阪瓦斯株式会社 | ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体 |
| EP4256966A4 (en) * | 2021-06-01 | 2024-12-11 | Osaka Gas Co., Ltd. | 3-hydroxybutyric-acid-containing oil and fat composition |
| US20240342121A1 (en) * | 2021-07-09 | 2024-10-17 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
| IT202100020441A1 (it) * | 2021-07-30 | 2023-01-30 | Unichem Estense S R L | Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici |
| CN113712140A (zh) * | 2021-09-13 | 2021-11-30 | 珠海麦得发生物科技股份有限公司 | 一种含(r)-3羟基丁酸的固体饮料及其制备方法 |
| CA3236459A1 (en) * | 2021-11-04 | 2024-05-11 | Gleb ANDRYIANAU | Ketone precursors and methods therefor |
| IL312317B2 (en) * | 2021-11-12 | 2025-04-01 | Arxada Ag | Polyol-derived compounds |
| AU2022417093A1 (en) * | 2021-12-14 | 2024-06-13 | Suntory Holdings Limited | Beverage containing 3-hydroxybutyric acid and lower aliphatic alcohol, and method for improving taste |
| WO2023112818A1 (ja) * | 2021-12-14 | 2023-06-22 | サントリーホールディングス株式会社 | 炭酸飲料及び炭酸飲料の炭酸感を増強する方法 |
| JP7223193B1 (ja) | 2022-05-26 | 2023-02-15 | 大阪瓦斯株式会社 | 内臓脂肪低減剤およびその用途 |
| CN116966173A (zh) * | 2023-06-15 | 2023-10-31 | 浙江大学 | 3-羟基苯乙酸在制备改善非酒精性脂肪肝药物中的应用 |
| CN118903420A (zh) * | 2024-07-02 | 2024-11-08 | 南方医科大学 | Irf4抑制剂在治疗非酒精性脂肪性肝炎的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1248321B (it) * | 1991-05-15 | 1995-01-05 | Sigma Tau Ind Farmaceuti | Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie |
| JP4740426B2 (ja) * | 1997-03-17 | 2011-08-03 | ビーティージー・インターナショナル・リミテッド | 治療用組成物 |
| US6323237B1 (en) * | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US20090253781A1 (en) | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
| AU751610B2 (en) * | 1997-12-22 | 2002-08-22 | Tepha, Inc. | Polyhydroxyalkanoate compositions having controlled degradation rates |
| US6753384B2 (en) * | 2000-07-14 | 2004-06-22 | Metabolix, Inc. | Polyurethanes obtained from hydroxyalkanoates and isocyanates |
| US20060280721A1 (en) * | 2003-06-03 | 2006-12-14 | The Gov Of Usa Represented By Secretary Of Dpt Of | Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives |
| SE0400355D0 (sv) * | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
| US7947736B2 (en) | 2004-07-16 | 2011-05-24 | Btg International Limited | Oligomeric compounds |
| US7485743B2 (en) | 2004-07-20 | 2009-02-03 | Btg International Limited | Oligomeric ketone compounds |
| WO2008110034A1 (en) * | 2007-03-14 | 2008-09-18 | Shantou University | 3-hydroxy fatty acid and its derivatives for improving of learning and/or memory of subjects |
| CN106038532B (zh) | 2008-01-04 | 2019-05-14 | 牛津大学科技创新有限公司 | 用作降低血脂药剂的酮体和酮体酯 |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| PL3296284T3 (pl) * | 2008-08-21 | 2022-06-13 | The Government Of The United States Of America, As Repres. By The Secretary Of Health And Human Services, Nat. Inst. Of Health | Nieterapeutyczne zastosowanie estru hydroksymaślanowego |
| JPWO2011078204A1 (ja) | 2009-12-24 | 2013-05-09 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
| US8865641B2 (en) * | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
| GB201206192D0 (en) * | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
| EP2984066B1 (en) | 2013-03-14 | 2017-02-01 | Oxford University Innovation Limited | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
| PE20151949A1 (es) | 2013-03-19 | 2016-01-05 | Univ South Florida | Composiciones y metodos para producir cetosis elevada y sostenida |
| EA201592020A1 (ru) * | 2013-04-22 | 2016-05-31 | Кадила Хелзкэр Лимитед | Новая композиция для неалкогольной жировой болезни печени (нажбп) |
| US11814664B2 (en) * | 2013-05-24 | 2023-11-14 | Genomatica, Inc. | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate |
| GB201314127D0 (en) | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
| US20150283163A1 (en) | 2014-04-04 | 2015-10-08 | Organic Medical Ventures, L.L.C. | Muscle treatment composition and method making same |
| WO2016123229A1 (en) * | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
| CA2979033A1 (en) * | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| CA3021784A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| GB201710229D0 (en) | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
-
2017
- 2017-06-27 GB GBGB1710229.4A patent/GB201710229D0/en not_active Ceased
-
2018
- 2018-06-22 GB GB1810300.2A patent/GB2567273B/en active Active
- 2018-06-22 EP EP18737388.1A patent/EP3644982B1/en active Active
- 2018-06-22 CA CA3066948A patent/CA3066948A1/en active Pending
- 2018-06-22 DK DK18737388.1T patent/DK3644982T3/da active
- 2018-06-22 AU AU2018293398A patent/AU2018293398B2/en active Active
- 2018-06-22 US US16/626,293 patent/US12439944B2/en active Active
- 2018-06-22 WO PCT/GB2018/051752 patent/WO2019002828A1/en not_active Ceased
- 2018-06-22 ES ES18737388T patent/ES2945964T3/es active Active
- 2018-06-22 KR KR1020207002473A patent/KR102680437B1/ko active Active
- 2018-06-22 CN CN201880042880.5A patent/CN110869012B/zh active Active
- 2018-06-22 PL PL18737388.1T patent/PL3644982T3/pl unknown
- 2018-06-22 TW TW107121496A patent/TWI811222B/zh active
- 2018-06-22 JP JP2019572783A patent/JP7374000B2/ja active Active
- 2018-06-22 EP EP23161905.7A patent/EP4215189A1/en active Pending
-
2023
- 2023-06-30 JP JP2023107837A patent/JP7632979B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527547A5 (enExample) | ||
| JP7261850B2 (ja) | 肝毒性および脂肪性肝疾患の処置に有効な化合物およびその使用 | |
| US20200101030A1 (en) | Multibiotic agents and methods of using the same | |
| Cheng et al. | Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity | |
| JP5561700B2 (ja) | 新規糖脂質及びその用途 | |
| US20220409650A1 (en) | Compositions and methods for ascaroside modification of mammalian microbiota | |
| JP2011502174A5 (enExample) | ||
| CN110183431B (zh) | 一类用于肝病治疗或预防的化合物 | |
| JP5890043B2 (ja) | 抗癌活性を有する２−デオキシ単糖の新規なアセテート | |
| US20200254105A1 (en) | Drug composition for parenteral administration | |
| JP2019534273A (ja) | モノアセチルジアシルグリセロール化合物を含有する肝炎の予防または治療用組成物 | |
| JP6377713B2 (ja) | 薬剤 | |
| US20090326259A1 (en) | NF-Kappabeta Activation Inhibitor | |
| JP6157041B2 (ja) | ＰＰＡＲγ活性化剤、抗肥満剤及び抗糖尿病剤 | |
| JP2020026434A (ja) | 癌治療剤 | |
| TW202237073A (zh) | 官能化長鏈烴單羧酸及二羧酸及其衍生物以及其於預防或治療疾病之用途 | |
| EP3728280A1 (en) | Method for improving the oral bioavailability of a drug | |
| KR20200080138A (ko) | 함초 추출물을 포함하는 골 질환 또는 갱년기 질환의 예방 또는 치료용 조성물 | |
| JP6043997B2 (ja) | 炎症性サイトカインの機能を抑制する炎症性疾患治療剤 | |
| US8614250B2 (en) | Uses of adipic acid | |
| JPWO2019234402A5 (enExample) | ||
| TWI797455B (zh) | 安卓錠化合物用於預防或治療非酒精性脂肪肝病的用途 | |
| JP2001226263A (ja) | 肥満予防剤 | |
| JPWO2020070506A5 (enExample) | ||
| WO2025158806A1 (ja) | 代謝機能不全に関連した脂肪性肝疾患の予防又は改善剤 |